Identification of Sinigrin as Active Compound of Rape Pollen for Treating Benign Prostatic Hyperplasia Through PI3K/AKT/mTOR Axis.

IF 6.1 2区医学 Q1 CHEMISTRY, MEDICINAL

Phytotherapy Research Pub Date : 2025-05-08 DOI:10.1002/ptr.8447

Bingliang Chen, Yingchao Wang, Guoda Song, Meicheng Liu, Peng Lv, Bin Yang, Hui Zhuge, Yu Tang, Yi Wang, Jianbiao Yao, Jianfang Wang, Jihong Liu, Xiaming Liu

{"title":"Identification of Sinigrin as Active Compound of Rape Pollen for Treating Benign Prostatic Hyperplasia Through PI3K/AKT/mTOR Axis.","authors":"Bingliang Chen, Yingchao Wang, Guoda Song, Meicheng Liu, Peng Lv, Bin Yang, Hui Zhuge, Yu Tang, Yi Wang, Jianbiao Yao, Jianfang Wang, Jihong Liu, Xiaming Liu","doi":"10.1002/ptr.8447","DOIUrl":null,"url":null,"abstract":"<p><p>Benign prostatic hyperplasia (BPH) is a common proliferative disease in older males. PuleanPian, containing rape pollen (RP), is a certified BPH medicine, but its main active compound and mechanism are unknown. This study aims to identify the main active compound of RP for the treatment of BPH. BPH rat models were induced with estradiol/testosterone (E2/T) and treated with RP or its alcohol extract (ALRP). RNA-seq and metabolomics were conducted, and RP compounds were identified via liquid chromatography-mass spectrometry (LC-MS). In vitro experiments used BPH-1 and RWPE-1 cells. E2/T induced BPH symptoms, alleviated by RP and ALRP treatment. RP possibly acts through phosphatidylinositol-3-kinase (PI3K)/AKT pathways, promoting autophagy. LC-MS identified five main RP compounds, with sinigrin implicated in BPH treatment via the PI3K/AKT(AKT Serine/Threonine Kinase 1)/mammalian target of rapamycin (mTOR) axis. Sinigrin may be the active compound in RP for BPH treatment, acting through the PI3K/AKT/mTOR axis.</p>","PeriodicalId":20110,"journal":{"name":"Phytotherapy Research","volume":" ","pages":""},"PeriodicalIF":6.1000,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Phytotherapy Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ptr.8447","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Benign prostatic hyperplasia (BPH) is a common proliferative disease in older males. PuleanPian, containing rape pollen (RP), is a certified BPH medicine, but its main active compound and mechanism are unknown. This study aims to identify the main active compound of RP for the treatment of BPH. BPH rat models were induced with estradiol/testosterone (E2/T) and treated with RP or its alcohol extract (ALRP). RNA-seq and metabolomics were conducted, and RP compounds were identified via liquid chromatography-mass spectrometry (LC-MS). In vitro experiments used BPH-1 and RWPE-1 cells. E2/T induced BPH symptoms, alleviated by RP and ALRP treatment. RP possibly acts through phosphatidylinositol-3-kinase (PI3K)/AKT pathways, promoting autophagy. LC-MS identified five main RP compounds, with sinigrin implicated in BPH treatment via the PI3K/AKT(AKT Serine/Threonine Kinase 1)/mammalian target of rapamycin (mTOR) axis. Sinigrin may be the active compound in RP for BPH treatment, acting through the PI3K/AKT/mTOR axis.

查看原文本刊更多论文

通过PI3K/AKT/mTOR轴鉴定油菜花粉中紫荆素治疗前列腺增生的活性成分。

良性前列腺增生（BPH）是老年男性常见的增生性疾病。普leanpian含有油菜花粉（RP），是一种经认证的BPH药物，但其主要活性成分和作用机制尚不清楚。本研究旨在鉴定RP治疗BPH的主要活性化合物。用雌二醇/睾酮（E2/T）诱导BPH大鼠模型，用RP或其醇提物（ALRP）治疗。进行RNA-seq和代谢组学分析，并通过液相色谱-质谱（LC-MS）对RP化合物进行鉴定。体外实验采用BPH-1和RWPE-1细胞。E2/T诱导BPH症状，RP和ALRP治疗减轻。RP可能通过磷脂酰肌醇-3激酶(PI3K)/AKT通路起作用，促进自噬。LC-MS鉴定了5种主要的RP化合物，其中sinigrin通过PI3K/AKT(AKT丝氨酸/苏氨酸激酶1)/哺乳动物雷帕霉素靶点（mTOR）轴参与BPH的治疗。紫荆素可能是RP中治疗BPH的活性化合物，通过PI3K/AKT/mTOR轴起作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Phytotherapy Research 医学-药学

CiteScore

12.80

自引率

5.60%

发文量

325

审稿时长

2.6 months

期刊介绍： Phytotherapy Research is an internationally recognized pharmacological journal that serves as a trailblazing resource for biochemists, pharmacologists, and toxicologists. We strive to disseminate groundbreaking research on medicinal plants, pushing the boundaries of knowledge and understanding in this field. Our primary focus areas encompass pharmacology, toxicology, and the clinical applications of herbs and natural products in medicine. We actively encourage submissions on the effects of commonly consumed food ingredients and standardized plant extracts. We welcome a range of contributions including original research papers, review articles, and letters. By providing a platform for the latest developments and discoveries in phytotherapy, we aim to support the advancement of scientific knowledge and contribute to the improvement of modern medicine.